{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:14:07Z","timestamp":1789110847131,"version":"build-2803163510"},"reference-count":15,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Takeda"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2022,10,3]]},"DOI":"10.1080\/17474086.2022.2112171","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T11:43:05Z","timestamp":1661341385000},"page":"943-950","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["Real-world study of rurioctocog alfa pegol and emicizumab in US clinical practice among patients with hemophilia A"],"prefix":"10.1080","volume":"15","author":[{"given":"Shawn X.","family":"Sun","sequence":"first","affiliation":[{"name":"Takeda Development Center Americas, Inc, Global Evidence and Outcomes Department, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Frick","sequence":"additional","affiliation":[{"name":"Trio Health Inc, Analytics Department, Louisville, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Balasa","sequence":"additional","affiliation":[{"name":"Valley Chidren\u2019s Hospital, Hematology Department, Madera, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9415-9543","authenticated-orcid":false,"given":"Jonathan C.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Bleeding & Clotting Disorders Institute, Peoria, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"issue":"6","key":"cit0002","first-page":"479","volume":"17","author":"Aledort L","year":"2019","journal-title":"Blood Transfus"},{"key":"cit0003","unstructured":"ADYNOVATE (Antihemophilic Factor (Recombinant)) [package insert]. Shire Website; [updated 2021 Jun; cited 2021 Sept 1. Available from: https:\/\/www.shirecontent.com\/PI\/PDFs\/ADYNOVATE_USA_ENG.pdf"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-630897"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13119"},{"issue":"4","key":"cit0006","first-page":"492","volume":"26","author":"Aledort L","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"cit0007","first-page":"ABS070","volume":"27","author":"Journeycake J","year":"2021","journal-title":"Haemophilia"},{"key":"cit0008","volume-title":"Prescribing information","author":"HEMLIBRA (emicizumab-kxwh) injection","year":"2021"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803550"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14005"},{"key":"cit0011","unstructured":"Institute for Clinical and Economic Review. Valoctocogene roxaparvovec and emicizumab for hemophilia A without inhibitors: final policy recommendations; 2020 [cited 2021 Sept 20]. Available from: https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_Hemophilia-A_Key-Policy-Recommendations_112020.pdf"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13655"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1649378"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S167731"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.19406"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2022.2112171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T19:39:21Z","timestamp":1666294761000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2022.2112171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,3]]}},"alternative-id":["10.1080\/17474086.2022.2112171"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2022.2112171","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-03-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}